相关实验视频

Updated: May 6, 2026

Detection of Antibodies That Neutralize the Cellular Uptake of Enzyme Replacement Therapies with a Cell-based Assay

Detection of Antibodies That Neutralize the Cellular Uptake of Enzyme Replacement Therapies with a Cell-based Assay

Published on: September 10, 2018

抗体治疗中的Fc玛受体多态性:对提高产品质量的生物试验开发的影响

Julianne D Twomey¹, Sasha George¹, Baolin Zhang¹

¹Office of Pharmaceutical Quality Research, Office of Pharmaceutical Quality, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD 20993, United States.

Antibody therapeutics

|April 3, 2025

概括

在Fc玛受体 (FcγRs) 的遗传变异影响治疗抗体的有效性. 了解FcγR多态是优化生物测试的关键,以确保抗体产品质量的一致性和改善患者的治疗结果.

科学领域:

免疫学免疫学免疫学
药理学药理学是指药理学的学科.
生物技术是生物技术.

背景情况:

治疗性抗体的有效性通常取决于Fc介导的效应器功能.
这些功能涉及免疫细胞和抗体Fc区域上的Fc马受体 (FcγRs) 之间的相互作用.
FcγR多态性可以改变受体功能,影响治疗抗体结果.

研究的目的:

审查FcγR多态性对抗体治疗的影响.
突出FcγR多态性在开发和优化功能生物试验中的作用.
强调了解这些变异对于抗体产品质量控制的重要性.

主要方法:

关于FcγR多态性及其对抗体治疗的影响的文献综述.
分析FcγR变异在免疫细胞相互作用中的作用.
对生物试验开发和优化策略的检查,根据FcγR多态.

主要成果:

FcγR多态性显著影响治疗抗体的有效性.
这些遗传变异影响受体表达,亲和力和细胞功能.
了解FcγR多态性对于准确的生物试验设计至关重要.

结论:

FcγR多态是治疗抗体有效性的关键决定因素.
基于FcγR知识的功能生物测试的优化对于产品的表征至关重要.
精制的生物测试确保了一致的制造和潜在的更好的治疗结果.

关键词:

Fc 效应器的功能功能.在 FcγR 多态形态中.抗体疗法是一种抗体疗法.生物测试生物测试产品质量产品质量产品质量

更多相关视频

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies

Published on: May 22, 2020

Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety

Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety

Published on: September 15, 2023

相关概念视频

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...